5:51 PM
 | 
Mar 02, 2010
 |  BC Extra  |  Company News

AstraZeneca details restructuring plans

AstraZeneca plc (LSE:AZN; NYSE:AZN) released further details of plans to reorganize its R&D, including its intention to end discovery efforts in 10 indications. AstraZeneca plans to cease work in thrombosis, acid reflux, ovarian and bladder cancers, systemic scleroderma, schizophrenia, bipolar disorder, depression, anxiety and HCV....

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >